Want to see RNXT full AI Analyst Report?
EarningsQ2 2026 Earnings Report
RNXT Q2 2026 EPS Results
Actual EPS-$0.06
Consensus EPS-$0.07
Beat/MissBeat by +$0.01
One Year Ago EPS-$0.08
RNXT Q2 2026 Revenue Results
Actual Revenue$909.00K
Expected Revenue$704.00K
Beat/MissBeat by +$205.00K
YoY Revenue Growth+115.40%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeAfter Close
Conference CallWednesday, August 12, 2026
RNXT Upcoming Earnings
RenovoRx's next earnings date is estimated for November 16, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
RNXT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented substantial commercial and clinical progress: record revenue with strong sequential and year-over-year growth, expanding active sites and a robust pipeline, completion of phase 3 enrollment, high gross margins, and improving adjusted operating loss. Key risks highlighted include continued operating losses and high SG&A relative to current revenue, declining cash to $9.5M and dependence on rapid site conversions and remaining clinical events to achieve the projected revenue run rate and breakeven timeline. On balance, the call conveyed positive execution and momentum with identifiable near-term operational and timing risks.Company Guidance
Record Quarterly Revenue
Second quarter 2026 revenue of $909,000, the strongest quarter to date, up ~61% sequentially from $563,000 and up ~115% year-over-year from $422,000. Q2 revenue represented ~83% of full-year 2025 revenue ($1.1M).
Rapid Commercial Site Activation
Active commercial cancer centers increased from 16 to 21 during the quarter (>30% growth in one quarter). Management remains on pace for a target of 36 active centers by year-end 2026.
Expanding Customer Funnel
21 active centers plus 42 additional centers in various stages (total funnel of 63), a 31% increase over 48 centers reported in Q1, with 15 TIGeR-PaC trial sites positioned to transition to commercial use.
Strong Unit Economics and Gross Margin
Gross profit of $706,000 for the quarter with gross margin ~84% (consistent with ~85% in Q1), indicating strong underlying economics for RenovaCath.
Clinical Milestones and Evidence Build
Full enrollment completed in phase 3 TIGeR-PaC trial; trial to complete in H1 2027 after 86 events (78 events observed as of Aug 11, 2026) with topline data expected in H2 2027. Multiple peer-reviewed publications and a PK sub-study supporting targeted delivery were announced/near publication.
Commercial Expansion Beyond Pancreatic Cancer
First commercial clinical use of RenovaCath in sarcoma treatment reported, demonstrating physician-driven expansion beyond LAPC and potential broader device indications within FDA cleared fields of use.
Improving Operating Performance and Guidance Tightening
Loss from operations improved slightly to ~$3.4M (vs ~$3.5M prior quarter); adjusted operating loss excluding noncash stock comp decreased by ~$370,000 sequentially. Company raised FY2026 revenue guidance to $3.75M–$4.25M (prior $3.0M–$4.0M), implying 241%–286% YoY growth vs 2025.
Repeat Orders and Physician Adoption
Continued strong repeat ordering from existing customers and over 900 procedures performed since FDA 510(k), indicating physician satisfaction and real-world adoption momentum.
RNXT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed